CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the popular penny stocks on Robinhood to buy. On March 23, Piper Sandler analyst Joseph Catanzaro raised his price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $12 from $10, while maintaining an Overweight rating. This move followed encouraging Phase 1 clinical data from CytomX’s lead drug candidate, varsetatug maseatecan, or varseta-M. CytomX Therapeutics (CTXM) Gains Analyst Confidence on Trial Progress Pixabay/Public domain Catanzaro noted tha ...